|
Market Closed -
Sao Paulo
02:23:48 12/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 93.24 BRL | +15.54% |
|
+2.89% | +41.36% |
| 11/11 | Amgen's Sjogren's drug cuts disease activity in trial | RE |
| 11/11 | Amgen Potential Autoimmune Drug Meets Primary Endpoint in Late-Stage Study | MT |
Company Valuation: Amgen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,26,718 | 1,40,139 | 1,54,142 | 1,40,103 | 1,76,250 | 2,53,206 | - | - |
| Change | - | 10.59% | 9.99% | -9.11% | 25.8% | 43.66% | - | - |
| Enterprise Value (EV) 1 | 1,51,990 | 1,69,779 | 2,07,811 | 1,88,229 | 2,21,725 | 2,92,567 | 2,87,006 | 2,80,127 |
| Change | - | 11.7% | 22.4% | -9.42% | 17.8% | 31.95% | -1.9% | -2.4% |
| P/E | 21.9x | 21.7x | 23.1x | 34.5x | 23x | 24.2x | 23x | 22.2x |
| PBR | 18.7x | 38.3x | 24.7x | 23.8x | 20.4x | 18.6x | 15.6x | 12.3x |
| PEG | - | 1.2x | 7.36x | -0.9x | 0.3x | 0.7x | 4.56x | 5.72x |
| Capitalization / Revenue | 4.88x | 5.32x | 5.47x | 4.19x | 4.8x | 6.41x | 6.13x | 5.86x |
| EV / Revenue | 5.85x | 6.45x | 7.37x | 5.63x | 6.03x | 7.41x | 6.95x | 6.48x |
| EV / EBITDA | 9.61x | 10.5x | 11.9x | 9.13x | 10.4x | 13.6x | 13x | 12.4x |
| EV / EBIT | 12.2x | 13.3x | 15.5x | 12.5x | 13.7x | 17x | 15.8x | 14.6x |
| EV / FCF | 18.1x | 19.3x | 28.2x | 18.1x | 27.4x | 25.9x | 18.2x | 16.1x |
| FCF Yield | 5.51% | 5.17% | 3.54% | 5.52% | 3.65% | 3.86% | 5.48% | 6.2% |
| Dividend per Share 2 | 7.04 | 7.76 | 8.52 | 9 | 9.52 | 10.09 | 10.66 | 11.14 |
| Rate of return | 3.13% | 2.95% | 2.96% | 3.45% | 2.91% | 2.16% | 2.28% | 2.38% |
| EPS 2 | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 | 19.37 | 20.34 | 21.13 |
| Distribution rate | 68.5% | 64.1% | 68.2% | 119% | 66.9% | 52.1% | 52.4% | 52.7% |
| Net sales 1 | 25,979 | 26,323 | 28,190 | 33,424 | 36,751 | 39,475 | 41,290 | 43,225 |
| EBITDA 1 | 15,822 | 16,178 | 17,470 | 20,620 | 21,370 | 21,482 | 22,113 | 22,523 |
| EBIT 1 | 12,424 | 12,761 | 13,399 | 15,028 | 16,203 | 17,213 | 18,128 | 19,145 |
| Net income 1 | 5,893 | 6,552 | 6,717 | 4,090 | 7,711 | 10,521 | 11,027 | 11,638 |
| Net Debt 1 | 25,272 | 29,640 | 53,669 | 48,126 | 45,475 | 39,361 | 33,800 | 26,921 |
| Reference price 2 | 224.97 | 262.64 | 288.02 | 260.64 | 327.31 | 468.25 | 468.25 | 468.25 |
| Nbr of stocks (in thousands) | 5,63,266 | 5,33,579 | 5,35,178 | 5,37,533 | 5,38,481 | 5,40,911 | - | - |
| Announcement Date | 07/02/22 | 31/01/23 | 06/02/24 | 04/02/25 | 03/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 41.91x | 14.16x | 30.08x | 0.48% | 1,27600Cr | |
| 41.09x | 6.89x | 19.39x | 1.9% | 68TCr | |
| 37.85x | 8.58x | 17.73x | 2.35% | 52TCr | |
| 21.6x | 5.24x | 13.12x | 2.49% | 39TCr | |
| 105.09x | 5.99x | 25.53x | 2.29% | 36TCr | |
| 23.85x | 5.92x | 14.34x | 2.69% | 31TCr | |
| 24.15x | 4.85x | 13.63x | 1.8% | 29TCr | |
| 24x | 7.37x | 13.6x | 2.17% | 25TCr | |
| -40.15x | 7.43x | 46.76x | 1.93% | 21TCr | |
| Average | 31.04x | 7.38x | 21.58x | 2.01% | 48TCr | |
| Weighted average by Cap. | 37.23x | 8.89x | 22.59x | 1.68% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMGN Stock
- AMGN34 Stock
- Valuation Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
